Experiments conducted on PBMCs derived from 14 individuals with advanced-stage melanoma (stage III or IV) demonstrate that the inhibition of PD-1 with pembrolizumab can enhance the production of cytotoxic T lymphocytes that specifically target melanoma antigens and prevent Treg from limiting the function of these cytotoxic T lymphocytes [66]. Here, PDCD1 is linked to melanoma.